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A B S T R A C T
Objective: The most common sites of colorectal cancer (CRC) recurrence are the local tissues, liver or
lungs. The objective was to identify risk factors associated with the primary CRC tumor and cancer
recurrence in these anatomical sites.
Methods: Retrospective, longitudinal analyses of data on CRC survivors. Multivariable Cox regression
analysis was performed to examine the association between possible cofounders with recurrence to
various anatomical sites.
Results: Data for 10,398CRC survivors (tumor location right colon = 3870, left colon = 2898, high
rectum = 2569, low rectum = 1061) were analyzed; follow up time was up to ﬁve years. Mean age at
curative surgery was 71.5 (SD 11.8) years, 20.2% received radio-chemotherapy, stage T3 (64.4%) and N0
(65.1%) were most common. Overall 1632 (15.7%) had cancer recurrence (Isolated liver n = 412, 3,8%;
isolated lung n = 252, 2,4%; isolated local n = 223, 2.1%). Risk factors associated with recurrent CRC were
identiﬁed, i.e. isolated liver metastases (male: Adjusted Hazard Ratio (AHR) 1,45; colon left: AHR 1,63;
N2 disease: AHR 3,35; T2 disease: AHR 2,82), isolated lung metastases (colon left: AHR 1,53; rectum high:
AHR 2,48; rectum low: AHR 2,65; N2 disease 3,76), and local recurrence (glands examined < 12: AHR
1,51; CRM <3 mm: AHR 1,60; rectum high: AHR 2,15; N2 disease: AHR 2,58) (all p values <0001).
Conclusion: Our study ﬁnds that the site of the primary CRC tumor is associated with location of
subsequent metastasis. Left sided colon cancers have increased risk of metastatic spread to the liver,
whereas rectal cancers have increased risk of local recurrence and metastatic spread to the lungs. These
results, in combination with other risk factors for CRC recurrence, should be taken into consideration
when designing risk adapted post-treatment CRC surveillance programs.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Colorectal cancer (CRC) is among the most common types of
cancer in both genders; approximately 2/3 is cured by surgery with
or without radio-chemotherapy. The overall ﬁve-year survival rate
in 2004–2008 in Norway was 58% for both colon cancer and rectal* Corresponding author at: Department of Surgery, Hammerfest Hospital,
Sykehusveien 35, 9613 Hammerfest, Norway.
E-mail address: knut.magne.augestad@telemed.no (K.M. Augestad).
http://dx.doi.org/10.1016/j.canep.2015.07.009
1877-7821/ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article uncancer [1]. The only chance for cure of recurrent CRC is by surgical
resection, most commonly performed for isolated metastases to
the lungs or liver [2,3]. The 5-year overall survival rate after
metastasis resection (i.e. R0 resections) varies from 25% to 58% for
patients with liver metastases and 24–52% for patients with lung
metastases [2,3].
Most CRC survivors are enrolled in post-treatment surveillance
programs, aiming to detect recurrent disease in an early stage, as
this has been shown to improve overall survival [4]. Well-known
risk factors of recurrent disease are advanced tumor stage, lymph
node involvement, certain histological subtypes, surgicalder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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factors are microsatellite instability and radio chemotherapy
among others [1,5–11]. However, there exist uncertainties related
to these risk factors and their association with cancer recurrence
and spread pattern to the liver, lungs and the local tissue [8,12–17].
This uncertainty is also reﬂected in the considerable variations of
national surveillance guidelines, i.e. different diagnostic tests,Table 1
Demographics.
Variable Colon right
n (%)
Colon left
n (%)
p 
Total n 3870 2898 
Female 1626 (42.0) 1546 (53.3) <0
Male 2244 (58.0) 1352 (46.7) 
Mean age (SD) 74.0 (11.2) 70.5 (11.9) <0
Surveillance months median (IQR) 36 (24–52) 
Radiochemotheraphy
Chemo 586 (15.1) 542 (18.7) <0
Preoperative radiation NAb NAb
Postoperative radiation NAb NAb
Total radiochemo 586 (15.1) 542 (18.7) <0
Missing 331 (8.6) 236 (8.1) 
Colon cancer surgery
Right-sided hemicolectomy 3150 (81.4) NA 
Left-sided hemicolectomy NA 562 (22.1) 
Sigmoidresection NA 1446 (50.0) 
Other colon surgery 221 (5.7) 167 (5.7) 
Rectal cancer surgery
Hartmann – – 
Low anterior resection – – 
Abdominoperineal resection – – 
Proctocolectomy – – 
Missing 499 (12.9) 723 (24.9) 
Stoma 30 (0.8) 92 (3.2) <0
Missing 1726 (44.6) 1196 (41.2) 
Complications
Perforation of tumor 30 (0.8) 29 (1.0) 0.5
Missing 331 (8.5) 236 (8.1) 
Perforation bowel wall 47 (1.2) 58 (2.0) 0.0
Missing 331 (8.5) 236 (8.1) 
Anastomosis leakage 142 (3.7) 127 (4.4) 0.3
Missing 331 (8.5) 236 (8.1) 
T stage <0
T1 133 (3.4) 156 (5.4) 
T2 623 (16.1) 455 (15.7) 
T3 2703 (69.8) 1998 (68.9) 
T4 367 (9.5) 208 (7.2) 
Missing 44 (1.1) 81 (2.8) 
Lymph node status 0.0
N0 2497 (64.5) 1864 (64.3) 
N1 816 (21.1) 661 (22.8) 
N2 512 (13.2) 333 (11.5) 
Missing 45 (1.2) 40 (1.4) 
Distal resection margins <0
1–5 mm 8 (0.2) 26 (0.9) 
6–15 mm 70 (1.8) 116 (4.0) 
16–30 mm 242 (6.25) 547 (18.9) 
>30 mm 2901 (75.0) 1920 (66.3) 
Missing 649 (16.7) 289 (9.9) 
CRM <0
CRM 0–3 mm 279 (7.2) 163 (5.6) 
CRM 4–10 mm 357 (9.2) 232 (8.0) 
CRM > 10 mm 1789 (46.2) 1571 (54.2) 
Missing 1445 (37.3) 932 (32.1) radiological target organs related to risk of metastases and timing
of tests [18–21].
In this study, we aimed to identify risk factors that were
associated with cancer recurrence in the liver, lungs and the local
tissue. We were particularly interested in isolated metastatic
recurrences, as these recurrences have a higher probability of
surgical cure. As the primary CRC tumor site has been reported to
impact metastatic spread pattern, we were particularly interestedRectum high
n (%)
Rectum low
n (%)
p Total
n (%)
2569 1061 10398
.001 1491 (58.0) 602 (56.7) 0.47 5133 (49.4)
1078 (42.0) 459 (43.3) 5265 (50.6)
.001 69.5 (11.8) 69.7 (12.0) 0.59 71.5 (11.8)
41 (25–60) 38 (25–55)
.001 304 (11.8) 177 (16.7) <0.001 1609 (15.5)
357 (13.9) 304 (28.6) <0.001 661 (18.2)
128 (5.0) 90 (8.5) <0.001 218 (6.0)
.001 567 (22.0)a 404 (38.0)a <0.001 2099(20.2)a
220 (2.6) 91 (0.8) 615 (5.91)
– – 3182 (30.6)
– – 642 (6.2)
– – 1449 (13.9)
– – 388 (3.7)
250 (9.7) 54 (5.1) 304 (2.9)
2114 (82.3) 123 (11.6) 2237 (21.5)
172 (6.7) 873 (82.3) 1045 (10.1)
18 (0.7) 8 (0.8) 26 (0.3)
15 (0.6) 3 (0.3) 1125 (10.8)
.001 814 (31.7) 91 (8.8) <0.001 1027 (10.0)
601 (23.4) 952 (89.7) 4475 (43.0)
2 55 (2.14) 41 (3.9) <0.001 164 (1.5)
111 (4.3) 64 (6.0) 742 (7.1)
3 79 (3.1) 61 (5.8) <0.001 245 (2.4)
111 (4.3) 64 (6.0) 742 (7.1)
 158 (6.2) 15 (1.4) <0.001 442 (4.3)
730 (28.4) 950 (89.5) 2247 (21.6)
.001 <0.001
234 (9.1) 88 (8.3) 611 (5.8)
704 (27.4) 384 (36.1) 2166 (20.8)
1490 (58.0) 514 (48.4) 6705 (64.4)
121 (4.7) 69 (6.5) 765 (7.4)
20 (0.8) 6 (0.6) 151 (1.45)
7 0.002
1674 (65.1) 736 (69.3) 6771 (65.1)
606 (23.6) 191 (18.0) 2274 (21.8)
268 (10.4) 121 (11.4) 1234 (11.8)
21 (0.8) 13 (1.23) 119 (1.1)
.001 <0.001
63 (2.5) 58 (5.5) 155 (1.5)
410 (16.0) 172 (16.2) 768 (7.5)
868 (33.8) 309 (29.1) 1966 (19.0)
987 (38.4) 372 (35.0) 6180 (59.4)
241 (9.4) 150 (14.4) 1329 (12.8)
.001 <0.001
310 (12.0) 244 (23.0) 996 (9.5)
582 (22.6) 359 (33.8) 1530 (14.7)
1033 (40.2) 187 (17.6) 4580 (44.0)
644 (25.0) 271 (25.5) 3292 (31.6)
Table 1 (Continued)
Variable Colon right
n (%)
Colon left
n (%)
p Rectum high
n (%)
Rectum low
n (%)
p Total
n (%)
Lymph nodes examined <0.001 <0.001
8 (0.2) 10 (0.3) 48 (1.8) 34 (3.2) 100 (0.09)
1–12 1146 (29.6) 1144 (39.4) 1704 (66.3) 757 (71.3) 4751 (45.6)
>12 2669 (68.9) 1705 (58.8) 755 (29.3) 237 (22.3) 5366 (51.6)
Missing 47 (1.2) 39 (1.3) 62 (2.4) 33 (3.1) 181 (0.17)
Tumor differentiation <0.001 <0.001
Low 969 (25.0) 276 (9.5) 251 (9.7) 147 (13.8) 1643 (15.8)
Medium 2345 (60.5) 2115 (72.9) 2076 (80.8) 793 (74.7) 7329 (70.4)
High 335 (8.6) 336 (11.5) 127 (4.9) 42 (3.9) 840 (8.0)
Indifferent 40 (1.0) 4 (0.14) 3 (0.12) 1 (0.09) 48 (0.4)
Missing 181 (4.6) 167 (5.7) 112 (4.3) 78 (7.3) 538 (5.1)
Abbreviations: CRM: Circumferential-resection margin.
a Does not sum up as several patients received multiple treatment modalities, i.e. total radiochemo deﬁned as rectal cancer patients receiving chemotherapy and/or
preoperative radiation and/or postoperative radiation.
b According to national guidelines, colon cancers Dukes Stage C recive postoperative chemo. No colon cancers receive radiation.
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high rectal, low rectal) were associated with metastatic pattern
and subsequent risk factors of solid organ cancer recurrence. By
identifying CRC spread patterns, it may guide clinicians, research-
ers and decision makers to tailor risk adjusted post surgical
surveillance programs related to the primary CRC tumor location
and risk of metastases [22]. Accordingly, the objective of this study
was to identify independent associations between the primary CRC
tumor and isolated CRC recurrence site(s) that may guide the
design of postoperative CRC surveillance guidelines.
2. Materials and methods
2.1. Overview
We performed a retrospective longitudinal analysis of data
extracted from the Norwegian Colorectal Cancer Registry (NCCR), a
clinical quality registry within The Norwegian Cancer Registry
(NCR). The Norwegian Gastrointestinal Cancer Group, NCR, and the
Institutional Review Board at University Hospitals Case Medical
Center, Cleveland, Ohio, approved the project. All patient data were
de-identiﬁed at a patient and hospital level.
2.2. Data sources
In Norway, all patients diagnosed with malignant solid tumors
are mandatorily reported to the NCR (http://www.kreftregisteret.
no/en/), which ensures that more than 99 per cent of all new
cancers are recorded. [23]. Similarly, the system of compulsory
reporting to the Norwegian Death Registry ensures that all deaths
and their causes are registered. In addition, all cancer related
deaths are reported directly to NCR.
2.3. Patient population
All adult patients treated curatively for CRC in years 2001–
2010 by major (i.e. laparotomy or laparoscopic approach)
abdominal surgery were included in the analyses. For the purpose
of this analysis, subsamples of data from the Rectal Cancer Registry
and the Colon Cancer Registry were combined, i.e.:
Subsample 1: Patients with rectal cancer that were surgically
treated from 1st January, 2001 until 15th December, 2006 and
followed up to 15th December, 2008.
Subsample 2: Patients with colon cancer that were surgically
treated from 15th January, 2007 until 15th December, 2010 and
followed up to 31st December, 2012.2.4. Radiochemotheraphy, curative surgery and postoperative
surveillance
According to national guidelines, patients with ﬁxed, primarily
non-resectable rectal cancers, or with threatened resection
margins (CRM <3 mm on preoperative pelvic MRI scan) were to
receive radiotherapy (25 2-Gy doses) combined with chemothera-
py. Patients with intraoperative tumor perforation or with a
resection margin of 1 mm or less were to receive postoperative
radiotherapy (25 2-Gy doses) combined with chemotherapy.
Patients with Dukes C colon cancer were to receive adjuvant
chemotherapy for a period of 6 months postoperatively [19].
Modern principles of surgical treatment of CRC were recom-
mended, including total mesorectal excision (TME) for patients
with rectal cancer, and at least D2 resections for colon cancers [24].
Postoperatively, all patients younger than 75 years were
included in a high intensive surveillance program. The national
guidelines recommended a 5-year surveillance program with
periodic clinical consultations, measurement of carcinoembryonic
antigen (CEA) every third month, colonoscopy and radiological
tests (liver ultrasound, chest X-ray). In 2010, the CRC surveillance
guidelines were revised, and measurements of CEA every six
month and CT abdomen, CT thorax, ultrasound of liver at a regular
basis up to ﬁve years after curative surgery, were recommended.
Colonoscopy was recommended at ﬁve years after surgery, for
rectal cancer patient’s sigmoidoscopy was recommended every six
months up to ﬁve years after surgery [19].
Recurrent cancer diagnostics were performed either by radiology
(CTscans of lungs, liver or abdomen, chest X-rays, ultrasound of liver,
scintigraphy of skeleton, PET scans), colonoscopy, biopsy of
metastases, biopsy of local recurrence and detection of elevated
carcinoembryonic antigen (CEA). All cancer recurrences (pathology
descriptions, time of recurrence and anatomical location) were
reported to NCR by the diagnosing hospitals.
2.5. Inclusion and exclusion criteria
Patients considered surgically cured from CRC (n = 14522) were
included in the primary NCR datasets. Surgical cure was deﬁned as
no remaining tumor tissue identiﬁed in the postoperative
histological examination and no remaining macroscopic tumor
tissue identiﬁed by the operating surgeon. We excluded patients
surgically treated for rectal cancer before 2001 (n = 4013) due to
the reported low adherence to TME in the 1990s, and variance in
use of radio-chemotherapy. [10,23] Also patients with missing data
on primary tumor site (24 colon and 64 rectal cancers), distant
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3 rectal cancers) or T0 (i.e. 16 premalignant rectal tumors) stage
were excluded, leaving our study population at 10,398 patients.
2.6. Variables of interest
2.6.1. Dependent variables
Dependent variables were metastases that may be completely
R0 resected i.e. isolated metastases in liver, lungs, peritoneum,
brain, distant lymph nodes, skeleton, and isolated local recurrence.
As cancer recurrence diagnosed simultaneously in liver and lungs
has a theoretical chance of surgical resection causing improved
survival (as described in Ref. [25]), this was analyzed as a
dependent outcome variable [25]. All other CRC recurrences
diagnosed simultaneously in two or more anatomical sites were
deﬁned as incurable (in surgical terms).
2.6.2. Confounders
The following variables were considered as possible cofounders
in bivariate and multivariate analysis: patient age and gender,
preoperative or postoperative radio-chemotherapy, surgical com-
plications (tumor perforation, anastomoses leakage, bowel perfo-
ration), distal resection margins, circumferential margin, number
of lymph nodes examined, tumor differentiation, T stage, N stage,
and time of index surgery (Table 1).
2.6.3. Main independent variable
Anatomical site of the primary CRC tumors was classiﬁed into
four anatomical subgroups: right-sided colon cancers (including
colon transversum), left sided colon cancers (from the left ﬂexure
to sigmoid), high rectal cancers (5 to 15 cm from the anal verge),
and low rectal cancers (0 to <5 cm from the anal verge).
Anatomical location of a rectal tumor was deﬁned based on the
recorded distance (measured in millimeters) from the anal verge to
the lower edge of the tumor measured by a rigid scope. Anatomical
location for colon tumors was deﬁned based on ICD-10 codes (right
sided: C18.0, C18.1, C18.2, C18.3, C18.4; left sided: C18.5, C18.6,
C18.7, C18.8, C19.9).Fig. 1. Distribution of local and metastatic disease2.7. Statistical approach
Survival analysis was chosen instead of logistic regression in
order to take maximal advantage of the person-years of observa-
tion in the data.
To retain patients with missing values in the multivariable
analysis, a missing value category was created for categorical
variables. The mean distal margin value for rectal cancers and that
for colon cancers replaced the respective missing values for this
only continuous variable with missing values.
A composite radio-chemo variable was coded as 1 if a colon
cancer patient received chemotherapy, a rectal cancer patient
received chemotherapy or pre- or post-operative radiotherapy, 0 if
otherwise.
We compared the distribution of predictor variables among
locations of tumors at the primary site using chi square tests for
categorical variables and ANOVA for continuous variables. Similar
bivariate comparisons were done between anatomical locations of
primary tumors and sites of recurrence.
Time to cancer recurrence was compared among anatomical
locations of primary tumors using the log-rank test computed by
the Kaplan Meier method.
Those who died within 5 years were censored at death while
those who survived beyong ﬁve years were censored at 5 years.
Adjusted hazard ratios (AHR) for outcomes of overall recur-
rence, single metastasis to liver, single metastasis to lung, single
metastasis to peritoneum, and isolated local recurrences were
computed using multivariable Cox Proportional Hazard models.
These recurrence sites were chosen because of their frequency
and—in the case of isolated liver and lung metastases—because
they represent opportunities for possible cure of recurrent disease.
We included all variables determined apriori which were known
prognostic variables (risk factors) for metastases.
The adjusted hazard ratios were estimated using three sets of
statistical models, including isolated colon cancers (with right
sided colon cancer as reference, Fig. 2, Appendix A1), isolated
rectal cancers (with high rectal cancers as reference, Fig. 3,
Appendix A2), and colon and rectal cancers combined; left sided
colon cancers, high and low rectum cancers (with right sided colon
cancers as reference, Fig. 4, Appendix A3). after curative resection of colorectal cancer.
Fig. 2. Risk factors of recurrent cancer in the liver, lung and local tissue. Left colon compared to right colon cancer. Signiﬁcant adjusted hazard ratios are shown. A detailed
overview of hazard ratios, p values and conﬁdence intervals are provided in Appendix A1.
Fig. 3. Risk factors of recurrent cancer in the liver, lung and local tissue. High rectum compared to low rectum cancer. Signiﬁcant adjusted hazard ratios are shown. A detailed
overview of hazard ratios, p values and conﬁdence intervals are provided in Appendix A2.
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than 0.001 was denoted p < 0.001. All data processing and analyses
were performed using SAS for Windows version 9.3 (SAS Institute,
Inc., Cary, NC).
3. Results
3.1. Characteristics of primary disease and treatment
Over ten thousand (10,398) patients surgically cured for CRC
(right colon = 3870, left colon = 2898, high rectum = 2,569, low
rectum = 1061) were analyzed. Across all primary sites 2099
(20.2%) received either radiotherapy, chemotherapy or both (right
colon 15.1%, left colon 18.7%, high rectum 22.0%, low rectum 38.0%),
T3 tumors were most common (n = 6705 (64.4%), right colon 69.8%,left colon 68.9%, high rectum 58.0%, low rectum 48.4%) as was
disease without lymph node involvement (n = 6771 (65.1%), colon
right 64.5%, colon left 64.3%, high rectum 65.1%, low rectum 69.3%).
Other important patient, treatment and disease characteristics are
shown in Table 1.
3.2. Pattern of recurrent cancers
During the follow-up period, 1632 (15.6%) patients had
recurrent cancers: (right colon 11.2%, left colon 12.8%, high rectum
22.2%, low rectum 24.2%); (Table 2). A total of 412 patients suffered
from isolated liver metastases, anatomical site of primary CRC
tumor was strongly associated with this outcome (colon right
2.66%, colon left 4.45%, high rectal 5.29%, low rectal 4.15%,
p < 0.001) (Table 2). A total of 252 patients suffered isolated lung
Table 2
Anatomical site of metastases and local CRC recurrence after curative resection.
Recurrent
site
Colon right n = 3870 Colon left n = 2898 p High rectal n = 2569 Low rectal n = 1061 p Total
n = 10398
p
n (%) Time to
recurrence
Median (IQR)
n (%) Time to
recurrence
Median (IQR)
n (%) Time to
recurrence
Median (IQR)
n (%) Time to
recurrence
Median (IQR)
n (%)
bLiver 103 (2.66) 12 (7–21) 129 (4.45) 14 (7–21) <0.001 136 (5.29) 14 (7–24) 44 (4.15) 11 (6–21) 0.14 412 (3.8) <0.001
bLung 39 (1.01) 19 (13–27) 49 (1.69) 18 (13–27) 0.02 110 (4.28) 24 (13–37) 54 (5.09) 24 (13–31) 0.28 252 (2.4) <0.001
bPeritoneum 35 (0.90) 11 (7–20) 15 (0.52) 10 (7–20) 0.07 13 (0.51) 20 (10–36) 4 (0.38) 19.5 (12.5–21) 0.6 67 (0.64) 0.08
bBrain 4 (0.10) 7.5 (6–23) 2 (0.07) 5 (4–6) 0.63 5 (0.19) 4 (3–5) 3 (0.28) 7 (3–33) 0.6 14 (0.13) 0.3
bSkeleton 4 (0.10) 18 (5.5–35) 1 (0.03) 11 (11–11) 0.3 16 (0.62) 15.5 (5.5–38) 5 (0.47) 43 (25–53) 0.58 26 (0.25) <0.001
bLymph-
nodes
12 (0.31) 11 (7–18) 10 (0.35) 20.5 (12–25) 0.8 4 (0.16) 14 (6.5–20.5) 11 (1.04) 14 (5–20) <0.001 37 (0.35) <0.001
bOther 71 (1.83) 17 (9–22) 35 (1.21) 14 (9–24) 0.04 9 (0.35) 19 (8–26) 6 (0.57) 17.5 (14–29) 0.35 121 (1.1) <0.001
bLocal 43 (1.11) 15 (9–29) 33 (1.14) 20 (13–31) 0.91 102 (3.97) 17.5 (10–27) 45 (4.24) 20 (13.5–30) 0.7 223 (2.1) <0.001
Missing 5 (0.13) 22 10–38) 2 (0.07) 5 (4–6) 0.44 3 (0.12) 5 (0–12) 1 (0.09) 13 (13–13) 0.85 11 (0.01) 0.9
2 sites or
morea
116 (3.0) 13 (9–20) 96 (3.31) 14.5 (9–22) 0.46 173 (6.73) 16 (9–27) 85 (8.01) 17 (9–32) 0.17 470 (4.0) <0.001
Total 432 (11.2) 372 (12.8) 0.04 571 (22.2) 257 (24.2) 0.19 1632
(15.6)
<0.001
LN: Lymph nodes;
a Deﬁned as two or more sites of cancer metastases at time of diagnoses.
b Isolated cancer recurrence site.
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associated with this outcome (colon right 1.01%, colon left 1.69%,
high rectal 4.28%, low rectal 5.09%, p < 0.001). A total of
470 patients suffered recurrence in 2 sites or more (colon right
3.0%, colon left 3.31%, high rectal 6.73%, low rectal 8.01%, p < 0.001)
(Table 2). Fig. 1 describes in more detail the spread pattern, and its
association with the location of the primary CRC tumor.
3.3. Risk factors of isolated recurrence in liver, lungs and the local
tissue
We observed the following ﬁndings consistently across all
statistical analyses: more advanced stage tumor and tumor cells in
adjacent lymph nodes were associated with increased hazard ratio.
In contrast, more recent year of surgery was associated with
decreased hazard ratio.Fig. 4. Risk factors of recurrent cancer in the liver, lung and the local tissue. Right colon co
are shown. A detailed overview of hazard ratios, p values and conﬁdence intervals are3.3.1. Right sided relative to left sided colon cancer (Fig. 2,
Appendix A1):
Compared to right-sided colon cancers, left-sided colon cancers
were associated with increased hazard of liver metastases
(Adjusted Hazard Ratio (AHR) 1.68, p < 0.001) but not lung,
peritoneal or local spread. Other predictors of isolated liver
metastases were N2 disease (AHR 3.65, p < 0.001), T3 disease (AHR
4.79, p = 0.02) and year of surgery (AHR 0.83, p = 0.003).
Isolated lung metastasis was associated with tumor perforation
(AHR 5.38, p = 0.003), N2 disease (AHR 4.07, p < 0.001) and year of
surgery (AHR 0.74, p = 0.003). Isolated peritoneal recurrence was
associated with N2 disease (AHR 5.28, p < 0.001) and medium
tumor differentiation (AHR 0.34, p = 0.01). Local recurrence was
associated with N2 disease (AHR 3.18, p < 0.001) and medium
tumor differentiation (AHR 0.46, p = 0.03).mpared to left colon, high and low rectum cancers. Signiﬁcant adjusted hazard ratios
 provided in Appendix A3.
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There was no difference between low (0–5 cm) and high (6–
15 cm) rectal cancers in time to local recurrence or metastatic
pattern. Isolated liver metastases were associated with males (AHR
1.80, p = 0.0003) and N2 disease (AHR 3.32, p < 0.001). Time to
isolated lung metastases was associated with N2 disease (AHR
3.93, p < 0.001) and T3 disease (AHR 5.50, p = 0.003), whereas time
to local recurrence was associated with tumor perforation (AHR
1.87, p = 0.03), N2 disease (AHR 2.37, p < 0.001), and distal resection
margin (AHR 0.98, p = 0.002), age (AHR 1.01, p = 0.01), N2 disease
(2.37, p < 0.001), T3 tumors (AHR 3.69, p = 0.01), and year of surgery
(AHR = 0.88, p = 0.01) and less than 12 gland examined (AHR 2.24,
p < 0.001).
3.3.3. Right-sided colon cancer relative to left colon cancer, high and
low rectum cancer (Fig. 4, Appendix A3):
Isolated liver metastases were associated with left sided colon
cancer (AHR 1.63, p < 0.001), being male (AHR 1.45, p < 0.001),
N2 disease (AHR 3.35, p < 0.001) and stage T3 (AHR 5.35, p < 0.001)
and year of surgery (AHR 0.86, p < 0.001). Isolated lung metastases
were associated with high and low rectal cancers (high rectal AHR
2.48, p = 0.005; low rectal AHR 2.65, p = 0.008), N2 disease (AHR
3.76, p < 0.001), and T3 tumors (AHR 4.89, p < 0.001). Isolated
peritoneal recurrence was associated with N2 disease (AHR 5.45,
p < 0.001) and medium tumor differentiation (AHR 0.39, p = 0.02).
3.4. Disease free survival
Cumulative freedom from metastases at 5 years of follow up
was 88% for right sided colon cancers and 86% for left sided colon
cancers (p = 0.079). For rectal sites, cumulative freedom from
metastases at 5 years of follow up was 78% for high rectal cancers
and 75% for low rectal cancers (p = 0.15), (Fig. 5a and b).
4. Discussion
This represents one of the largest studies addressing the natural
history of metastatic CRC cancer. A large population surgically
cured of CRC was followed for up to ﬁve years after the initial
surgery, and the frequency of cancer recurrence in the liver, lungs,
local tissue and other organs are reported.
We have shown that anatomical location of the primary CRC
tumor is an independent predictor of recurrent cancer metastases,
i.e. left sided colon cancer had a 70% increased risk for isolated liver
metastases relative to right-sided colon cancers. High and low
rectal cancers, relative to right-sided colon cancers, had a greaterFig. 5. Kaplan Meier curves of time to any cancer recurrence stratiﬁed by primathan two-fold higher risk for isolated lung metastases. Finally, we
have identiﬁed the most important risk factors associated with
recurrent cancer disease in the liver, lung and the local tissue.
These ﬁndings suggest that the anatomical location of the primary
CRC tumor represent a natural framework for further development
of risk tailored personalized surveillance guidelines.
4.1. Comparison with existing literature
The anatomical pattern of recurrent cancer has been discussed
for several decades [26,27]. Today it is commonly accepted that six
different routes of colorectal cancer spread exist, i.e. direct spread,
transperiotoneal spread, implantation, lymphatic spread, hema-
togenous spread and venous extension [28].
Analysis of the distribution of metastatic disease in autopsy
series contributed to the development of a cascade hypothesis that
metastatic disease develops in discrete steps, ﬁrst to the liver, then
to the lung, and ﬁnally to other sites [15]. The cascade hypothesis is
not supported by our results, which show that single metastases to
the lungs and other peripheral anatomical sites are quite common,
especially for rectal cancers.
Several others have described the spread patterns of colon and
rectal cancers [8,12–14,29]. Hugen et al. reported that rectal
tumors, presented more frequently with extra-abdominal meta-
static sites such as lung (rectal tumors 42.0% versus colon tumors
30.7%; P < 0.0001). 8Ding et al. described a signiﬁcantly greater
tendency for low rectal tumors (<5 cm from the anal verge) to
metastasize to the lungs lung compared to higher rectal tumors
[12]. Although our ﬁndings conﬁrm an increased frequency of lung
metastases among those with rectal cancer, we found no difference
between high and low rectal cancers. Furthermore, none of these
studies have compared the spread patterns of the different
segments of colon and rectum, as we did in ours.
There exists limited evidence regarding the spread pattern from
colon cancers. Animal studies have demonstrated a streamlined
ﬂow of portal blood from colon to the to the liver which again
impact the metastatic pattern in the liver [30]. However, to our
knowledge, the association between left sided colon cancers and
isolated liver metastases, as we found in our study, is not reported
earlier.
4.2. Limitations and strengths
This study is limited by the inherent biases of large retrospec-
tive review. First, we acknowledge that data from different
recruitment periods may have introduced bias in the analyses.ry tumor site. (a) Right colon vs. left colon. (b) High rectum vs. low rectum.
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separate analyses of the colon cancer and rectal cancer patients
(Appendix A1–A2). Finally, we performed an overall analysis of the
whole colon and rectum, comparing the different segments
relative to right-sided colon cancers (Appendix A3).
Second, the recurrence rate of 11.8 % (n = 804) for colon cancer is
lower than expected. There have however been substantial
improvements in both colon and rectal cancer long-term survival
in recent years, and we believe our ﬁgures mirror this improved
survival trend for both colon and rectal cancers [1,31,32].
Thirdly, in this publication there is no information on the
number of patients who received a curative treatment for isolated
tumor recurrence. However the goal of this study was not to
demonstrate a clinical beneﬁt (number of successful R0 resections)
of intensive CRC surveillance, but to document an association
between primary tumor site and recurrence pattern. The next
logical step of our work will be to conduct this analysis.
Finally, a limitation related to secondary analyses might be the
quality of the data (completeness and accuracy) related to the data
reporting of local colon cancer recurrence, and of chemotherapy
use in colon cancers by hospitals to NCR. According to NCR, a
secondary quality control of these particular data elements has not
yet been performed. All other data variables used in this analysis
have been evaluated for completeness and accuracy by the NCR.
The strength is the size of the cohort and the long-term follow-
up period. Further, the Norwegian healthcare system and the
socioeconomic status of the Norwegian population are fairly
homogeneous, which should exclude major variation in access to,
delivery of, and compliance with healthcare and follow-up, and
allow population-based analysis without major confounders. At
the same time, this homogeneity may limit the generalizability
of our ﬁndings to other countries, especially ones with more
diverse populations, and those with no universal access to health
care.
4.3. Clinical implications
These ﬁndings may have clinical implications for how CRC
surveillance programs should be designed. In this study we have
focused on recurrences that may be surgically cured (isolated lung
metastases, liver metastases, local recurrence, peritoneal recur-
rence and combined liver and lung recurrence), which is
important, as the prognosis especially for resected liver and lung
metastases has signiﬁcantly improved during recent years. [2,3] In
the light of our results and other studies (i.e. Refs. [8,15–17,22,29]),
we believe that personalized, risk stratiﬁed surveillance programs
should be designed according to the location of the primary CRC
tumor, i.e.;
Liver oriented surveillance: There was a 70% higher risk of
isolated liver metastases in left-sided colon cancers, suggesting
that liver imaging should be scheduled more frequently in these
patients.
Lung oriented surveillance: Patients with rectal cancer had more
than double the risk to develop isolated lung metastases relative to
right-sided colon cancers, suggesting that this patient group should
be followed more aggressively for lung metastases by chest CT.
Local oriented surveillance: There was more than double the risk
to develop isolated local recurrence in high rectal cancers relative
to right-sided colon cancers, suggesting a more intensive surveil-
lance of local cancer recurrence in rectum, especially when there is
evidence of short distal resection margins.
We acknowledge that more research is needed before evidence-
based, risk-tailored surveillance programs can become a reality.
Large randomized trials comparing surveillance programs bring
new evidence to light, and simulation models may be used toestimate the optimal risk stratiﬁed surveillance programs
[22,32,33].
5. Conclusion
These results suggest that developing approaches for adjusting
the intensity of CRC surveillance tests (i.e. radiology, blood samples
and clinical examination) based on primary tumor location and
other risk factors for metastatic spread, may improve our ability to
detect colorectal cancer recurrences at a more treatable stage.
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Table A1
Adjusted hazard ratio CRC recurrence: right sided colon cancers relative to left sided colon cancers.
Variable Overall AHR
(95% CI)
p Liver only AHR
(95% CI)
p Lung only AHR
(95% CI)
p Peritoneum only AHR
(95% CI)
p Local only AHR
(95% CI)
p
Colon lefta 1.16 0.04 1.68 <0.001 1.49 0.07 0.68 0.22 1.07 0.75
(1.00–1.34) (1.28–2.02) (0.96–2.31) (0.36–1.27) (0.67–1.73)
Age 1 0.93 0.99 0.57 0.98 0.14 1.02 0.15 1.02 0.07
(0.99–1.00) (0.98–1.00) (0.96–1.00) (0.99–1.05) (0.99–1.04)
Perforation tumor 0.69 0.21 0.56 0.3 5.38 0.003 0.54 0.59 1.1 0.9
(0.39–1.23) (0.18–1.69) (1.73–16.68) (0.05–5.00) (0.22–5.51)
N 1b 2.38 <0.001 2.29 <0.001 2.79 <0.001 1.79 0.14 1.61 0.1
(1.98–2.85) (1.64–3.19) (1.62–4.80) (0.82–3.89) (0.90–2.88)
N 2b 4.24 <0.001 3.65 <0.001 4.07 <0.001 5.28 <0.001 3.18 <0.001
(3.50–5.13) (2.54–5.22) (2.24–7.37) (2.55–10.92) (1.73–5.84)
T 3c 4.63 <0.001 4.79 0.02 3.03 0.27 NA NA NA NA
(2.06–10.39) (1.17–19.52) (0.41–22.12)
T 4c 8.47 <0.001 5.02 0.03 3.35 0.26 NA NA NA NA
(3.70–19.36) (1.15–21.83) (0.40–27.61)
Year of surgery 0.83 <0.001 0.83 0.003 0.74 0.003 0.89 0.41 0.99 0.97
(0.77–0.88) (0.73–0.94) (0.60–0.90) (0.69–1.16) (0.80–1.23)
CRM 0–3 mmd 1.18 0.2 0.73 0.29 0.53 0.23 0.59 0.4 2.4 0.01
(0.91–1.54) (0.41–1.30) (0.19–1.43) (0.18–1.99) (1.15–4.98)
Glands examined
0e
4.86 0.04 2.59 0.57 53.4 0.99 0 0.99 0.03 0.99
(1.03–22.8) (0.09–74.0) (NA) (NA)
Differentiation
lowD
1.34 0.18 0.74 0.28 0.72 0.45 0.63 0.34 0.78 0.54
(0.87–2.05) (0.43–1.27) (0.31–1.66) (0.24–1.61) (0.35–1.73)
Differentiation
mediumf
1.09 0.64 0.87 0.55 0.7 0.3 0.34 0.01 0.46 0.03
(0.73–1.62) (0.56–1.36) (0.35–1.38) (0.13–0.77) (0.23–0.93)
Abbreviations: AHR: Adjusted hazard ratio; mm: millimeters; CRM: circumferential margin; NA: not applicable due to low n; CRM: circumferential margin; Non-signiﬁcant
confounders: male, age, radio-chemo; T2; distal resection margin; CRM > 3 mm; glands examined 1–12; tumor differentiation low and indifferent.
a Reference colon right.
b Reference N0 disease.
c Reference T1 disease.
d Reference CRM > 10 mm.
e Reference glands examined > 12.
f Reference tumor differentiation high.
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Adjusted hazard ratio CRC recurrence: high rectal cancers relative to low rectal cancers.
Variable Overall AHR
(95% CI)
p Liver only AHR
(95% CI)
p Lung only AHR
(95% CI)
p Peritoneum only AHR
(95% CI)
p Local only AHR
(95% CI)
p
Rectum lowa 0.91 0.31 0.91 0.66 1.11 0.6 0.41 0.17 0.69 0.08
(0.76–1.09) (0.59–1.38) (0.74–1.67) (0.11–1.49) (0.45–1.05)
Male 1.25 0.001 1.8 <0.001 1.22 0.21 0.57 0.26 1.05 0.73
(1.08–1.44) (1.31–2.49) (0.89–1.67) (0.21–1.51) (0.76–1.47)
Age 1 0.73 0.99 0.88 1 0.56 0.97 0.2 1.01 0.01
(0.99–1.00) (0.98–1.01) (0.99–1.01) (0.93–1.01) (1.00–1.03)
Radio-chemo 1.36 <0.001 1.49 0.01 1.31 0.11 1.12 0.83 0.98 0.92
(1.17–1.59) (1.08–2.07) (0.93–1.85) (0.37–3.34) (0.66–1.45)
Perforation tumor 0.94 0.67 0.64 0.2 0.98 0.96 1.99 0.41 1.87 0.03
(0.72–1.23) (0.33–1.26) (0.52–1.85) (0.37–10.52) (1.05–3.32)
Anastomoses
leakage
0.84 0.048 0.97 0.87 0.71 0.09 1.4 0.55 0.82 0.37
(0.70–0.99) (0.68–1.37) (0.48–1.05) (0.45–4.36) (0.53–1.26)
N1b 1.94 <0.001 2.22 <0.001 1.76 0.002 0.72 0.68 1.09 0.68
(1.65–2.29) (1.58–3.13) (1.21–2.56) (0.14–3.49) (0.71–1.65)
N2b 4.11 <0.001 3.32 <0.001 3.93 <0.001 4.92 0.007 2.37 <0.001
(3.44–4.91) (2.24–4.93) (2.63–5.87) (1.53–15.80) (1.54–3.65)
T2c 2.14 <0.001 2.84 0.08 2.92 0.07 0.36 0.32 1.9 0.23
(1.33–3.47) (0.86–9.33) (0.89–9.56) (0.05–2.70) (0.66–5.44)
T3c 4.17 <0.001 5.54 0.003 5.5 0.003 1.11 0.89 3.69 0.01
(2.62–6.61) (1.75–17.54) (1.73–17.46) (0.21–5.79) (1.34–10.1)
T4c 5.69 <0.001 3.87 0.04 5.41 0.01 0 0.98 7.28 <0.001
(3.38–9.55) (1.01–14.83) (1.43–20.35) (2.37–22.39)
Distal margin mm 0.99 0.01 1 0.45 0.99 0.44 0.99 0.71 0.98 0.002
(0.99–0.99) (0.99–1.01) (0.98–1.00) (0.96–1.02) (0.97–0.99)
Year of surgery 0.93 0.001 0.87 0.002 0.98 0.69 1.13 0.41 0.88 0.01
(0.89–0.97) (0.79–0.95) (0.88–1.08) (0.83–1.54) (0.79–0.98)
CRM 0–3 mmd 1.29 0.02 1.36 0.18 1.33 0.24 1.43 0.63 1.45 0.16
(1.04–1.60) (0.86–2.14) (0.82–2.15) (0.33–6.19) (0.85–2.47)
CRM 4–10 mmd 1.2 0.05 1.21 0.35 1.23 0.33 0.37 0.26 1.35 0.21
(0.99–1.45) (0.80–1.81) (0.81–1.86) (0.06–2.11) (0.84–2.17)
Table A2 (Continued)
Variable Overall AHR
(95% CI)
p Liver only AHR
(95% CI)
p Lung only AHR
(95% CI)
p Peritoneum only AHR
(95% CI)
p Local only AHR
(95% CI)
p
Glands examined
0e
2.14 0.002 1.71 0.37 0.84 0.82 10.79 0.05 4.97 0.001
(1.30–3.51) (0.51–5.67) (0.18–3.80) (0.95–122.0) 00.001
Glands examined
1–12e
1.27 0.003 1.1 0.55 0.98 0.91 1.48 0.51 2.24 <0.001
(1.08–1.50) (0.79–1.55) (0.69–1.39) (0.45–4.90) (1.42–3.53)
Abbreviations: AHR: Adjusted hazard ratio; mm: millimeters; CRM: circumferential margin; Non-signiﬁcant confounders: perforation of bowel wall; tumor differentiation.
a Reference rectum high.
b Reference N1 disease.
c Reference T1 disease.
d Reference CRM > 10 mm.
e Reference glands examined >12.
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Adjusted hazard ratio CRC recurrence: right sided colon cancers relative to left sided colon cancers, high and low rectum cancers.
Variable Overall AHR
(95%CI)
p Liver only AHR
(95%CI)
p Lung only AHR
(95%CI)
p Peritoneum only AHR
(95% CI)
p Local only AHR
(95% CI)
p
Colon lefta 1.14 0.07 1.63 <0.001 1.53 0.05 0.66 0.19 0.99 0.98
(0.98–1.31) (1.25–2.13) (0.99–2.35) (0.35–1.23) (0.62–1.58)
Rectum higha 1.25 0.07 1.01 0.95 2.48 0.005 0.93 0.92 2.15 0.03
(0.97–1.60) (0.65–1.66) (1.30–4.73) (0.26–3.31) (1.09–4.21)
Rectum lowa 1.21 0.18 0.89 0.7 2.65 0.008 0.652 0.61 1.54 0.26
(0.91–1.61) (0.49–1.61) (1.28–5.48) (0.12–3.38) (0.71–3.33)
Male 1.18 0.001 1.45 <0.001 1.23 0.1 0.75 0.26 1.13 0.36
(1.06–1.30) (1.18–1.76) (0.95–1.59) (0.46–1.23) (0.86–1.48)
Age 0.7 0.14 0.71 0.71 0.99 0.76 1.01 0.38 1.02 0.002
(0.99–1.00) (0.99–1.00) (0.98–1.00) (0.98–1.03) (1.01–1.03)
Radio-chemo 1.18 0.002 1.15 0.18 1.23 0.12 1.05 0.84 0.82 0.25
(1.06–1.31) (0.93–1.43) (0.94–1.62) (0.59–1.90) (0.59–1.14)
Perforation tumor 0.87 0.27 0.56 0.05 1.19 0.53 1.2 0.78 1.66 0.06
(0.72–1.17) (0.31–0.99) (0.68–2.06) (0.31–4.57) (0.97–2.82)
Perforation bowel wall 1.2 0.11 1.33 0.25 1.08 0.77 1.17 0.81 1.49 0.14
(0.95–1.50) (0.81–2.17) (0.62–1.89) (0.31–4.57) (0.86–2.56)
Anastomoses leakage 0.82 0.008 0.98 0.92 0.69 0.04 0.97 0.95 0.84 0.38
(0.71–0.95) (0.74–1.30) (0.49–0.98) (0.43–2.19) (0.58–1.22)
N 1b 2.09 <0.001 2.14 <0.001 1.98 <0.001 1.52 0.22 1.2 0.27
(1.85–2.35) (1.70–.70) (1.47–2.67) (0.77–2.98) (0.86–1.68)
N 2b 4.07 <0.001 3.35 <0.001 3.76 <0.001 5.45 <0.001 2.58 <0.001
(3.59–4.62) (2.58–4.34) (2.71–5.20) (2.99–9.94) (1.82–3.64)
T2c 2.16 <0.001 2.82 0.03 2.76 0.05 0.79 0.77 2.33 0.11
(1.42–3.28) (1.12–7.01) (0.99–7.73) (0.15–3.95) (0.82–6.58)
T3c 4.27 <0.001 5.35 <0.001 4.89 0.001 1.49 0.58 4.4 0.004
(2.86–6.37) (2.19–13.02) (1.80–13.27) (0.35–6.35) (1.61–11.98)
T4c 7 <0.001 4.96 0.001 5.12 0.003 2.97 0.16 10.31 <0.001
(4.58–10.69) (1.89–12.98) (1.70–15.42) (0.62–14.08) (3.57–29.78)
Distal margin mm 1 0.64 1 0.09 0.99 0.37 1 0.06 0.99 0.02
(0.99–1.00) (1.00–1.05) (0.99–1.00) (1.00–1.09) (0.98–0.99)
Year of surgery 0.9 <0.001 0.86 <0.001 0.93 0.13 1 0.93 0.9 0.04
(0.87–0.93) (0.80–0.92) (0.85–1.02) (0.83–1.22) (0.82–0.99)
CRM 0–3 mmd 1.27 0.003 1.1 0.56 1.05 0.8 0.87 0.75 1.6 0.03
(1.08–1.49) (0.79–1.52) (0.70–1.56) (0.38–1.99) (1.04–2.45)
CRM 4–10 mmd 1.21 0.007 1.16 0.29 0.98 0.95 0.57 0.22 1.31 0.17
(1.05–1.41) (0.87–1.54) (0.69–1.40) (0.23–1.41) (0.88–1.96)
Glands examined 0e 2.19 <0.001 1.55 0.42 1.08 0.91 6.84 0.04 3.52 0.005
(1.4–3.4) (0.52–4.59) (0.25–4.52) (1.07–43.6) (1.44–8.62)
Glands examined 1–12e 1.18 0.002 0.95 0.7 1.09 0.52 1.32 0.32 1.51 0.008
(1.06–1.32) (0.77–1.18) (0.82–1.44) (0.76–2.28) (1.11–2.06)
Tumor differentiation
lowf
1.14 0.2 0.89 0.63 0.93 0.83 0.62 0.28 0.83 0.58
(0.90–1.43) (0.56–1.51) (0.49–1.75) (0.25–1.49) (0.44–1.58)
Tumor differentiation
mediumf
0.88 0.2 0.92 0.7 0.93 0.81 0.39 0.02 0.75 0.31
(0.71–1.0) (0.62–1.37) (0.54–1.62) (0.17–0.86) (0.43–1.31)
Tumor differentiation
indifferentf
0.59 0.2 0 0.9 1.1 0.92 0.66 0.71 0.7 0.74
(0.24–1.47) (0.14–8.60) (0.07–5.67) (0.09–5.56)
Abbreviations: AHR: Adjusted hazard ratio; mm: millimeters; CRM: circumferential margin.
a Reference colon right.
b Reference N0 disease.
c Reference T1 disease.
d Reference CRM > 10 mm.
e Reference glands examined >12.
f Reference tumor differentiation high.
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